NCT05931224CompletedPhase 3
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial To Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D660 Monotherapy in Essential Hypertension Patients
Source: ClinicalTrials.gov · Last updated 4 Jun 2024
Brief summary (registry, in English)
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 346 (actual)
- First submitted
- 27 Jun 2023
- Start date
- 28 Jun 2023
- Primary completion date
- 13 May 2024
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Diseases
- High blood pressure
- NCT number
- NCT05931224
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 346
- From 28 Jun 2023 to the primary completion date, 13 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who are required to administer a combination of prohibited drugs specified in this plan during the clinical trial participation period
- Subjects who received other clinical trial drugs within 4 weeks of screening visit.
- Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug
Other illness
- Subjects with a history of secondary hypertension or suspected secondary hypertension
- Subjects with hypersensitivity or history of clinical trial drugs and similar drugs
- Subjects with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening
Other
- Subjects who are unable to participate in this clinical trial at the discretion of the investigator.
Who the study is looking for
- Subjects who are 19 years old or older.
- Subjects who have voluntarily decided to participate in this clinical trial and signed ICF.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.